Hundertmark Sarah

Clinical outcomes of the PAUL® glaucoma implant: One-year results.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy. An intraluminal prolene stent impedes hypotony in the early postoperative phase and enables further IOP lowering without additional interventions during the postoperative course.

Two-Year Clinical Outcomes of the PAUL Glaucoma Implant in White Patients With Refractory Glaucoma.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy.

Five-Year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.

Trabectome surgery is a safe and relatively effective procedure for lowering IOP, but most patients still need IOP-lowering agents, and a considerable proportion may need additional glaucoma surgery within a relatively short time.

Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.

PGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.

Clinical outcomes of the EyeWatch system: three-year results.

Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.

Clinical Outcomes of Intraluminal Stent Removal After PAUL Glaucoma Implant Surgery.

Removal of the prolene stent following PGI surgery effectively lowers IOP in the short term, with a moderate increase in IOP and need for pressure-lowering therapy over time.